Interim analysis of the OLYMPIA long-term extension in 508 adults with moderate-to-severe prurigo nodularis on nemolizumab: TEAEs in 89%, mostly mild/moderate; at week 100, 92% of evaluable patients achieved ≥4-point itch improvement (no control group).
RCTn = 508
Legat et al. Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis